AstraZeneca (GB:AZN) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable investment by purchasing 980 ordinary shares at a price of £101.70 each. This acquisition, announced on November 13, 2024, highlights confidence in the company’s robust position in the global biopharmaceutical market.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.